



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

July 2015





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.682.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

July 2015

N = 6937



Health Authority	Male	Female	All
FRASER	1294	395	1689
INTERIOR	341	94	435
NORTHERN	137	78	215
VANCOUVER COASTAL	3338	439	3777
VANCOUVER ISLAND	643	150	793
	<b>5753</b>	<b>1156</b>	<b>6909</b>
		<b>Unknown/not stated:</b>	<b>28</b>
		<b>Total:</b>	<b>6937</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2010 - July 2015)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2010 - July 2015)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (July 2010 - July 2015)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (July 2010 - July 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (July 2010 - July 2015)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (July 2010 - July 2015)





### 1.8 Active and Inactive Participants (July 2010 - July 2015)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (July 2010 - July 2015)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (July 2010 - July 2015)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(July 2010 - July 2015)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (July 2010 - July 2015)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(July 2010 - July 2015)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (July 2010 - July 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(July 2010 - July 2015)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (July 2010 - July 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT (July 2010 - July 2015)






1.18 Baseline CD4 for Antiretroviral First Starts (July 2010 - July 2015)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(July 2010 - July 2015)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (July 2010 - July 2015)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (July 2010 - July 2015)





## 2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	600	5	<40	4
1988	23	8	0	8	7	580	7	<40	4
1989	22	57	2	59	54	500	57	<40	4
1990	21	62	1	63	58	535	61	<40	4
1991	21	37	3	40	34	550	40	<40	4
1992	21	67	5	72	54	575	70	<40	4
1993	20	149	16	165	148	535	161	<40	4
1994	19	97	13	110	90	530	106	<40	4
1995	19	131	24	155	125	530	147	<40	4
1996	17	378	63	441	377	570	425	<40	4
1997	15	315	40	355	313	580	340	<40	3
1998	14	222	46	268	225	560	255	<40	4
1999	14	187	44	231	188	530	218	<40	3
2000	14	141	37	178	153	580	169	<40	3
2001	14	135	37	172	142	570	164	<40	3
2002	13	141	33	174	147	530	172	<40	3
2003	12	179	36	215	186	590	205	<40	3
2004	11	186	49	235	204	540	227	<40	3
2005	10	213	50	263	228	590	255	<40	4
2006	9	217	46	263	217	540	251	<40	3
2007	8	283	57	340	284	580	323	<40	3
2008	7	319	80	399	323	610	376	<40	3
2009	6	351	78	429	364	620	414	<40	3
2010	5	323	77	400	338	620	379	<40	3
2011	4	379	80	459	400	624	440	<40	3
2012	3	318	71	389	328	640	376	<40	3
2013	2	310	74	384	310	590	370	<40	3
2014	1	324	61	385	319	640	372	<40	3
2015	0	234	38	272	250	498	265	41	4
<b>Total:</b>		<b>5768</b>	<b>1161</b>	<b>6929</b>					

### Definitions:

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	782	2429	<40	2151	560
FEB-2014	6570	782	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1874	560
MAY-2014	6677	769	2120	<40	1887	560
JUN-2014	6644	784	1994	<40	1768	550
JUL-2014	6682	779	2179	<40	1930	550
AUG-2014	6703	774	2026	<40	1806	570
SEP-2014	6730	770	2284	<40	2003	550
OCT-2014	6760	763	2250	<40	1957	570
NOV-2014	6758	760	1920	<40	1706	580
DEC-2014	6771	765	1896	<40	1688	580
JAN-2015	6746	760	2428	<40	2110	580
FEB-2015	6797	753	1981	<40	1729	570
MAR-2015	6845	747	2175	<40	1886	570
APR-2015	6857	739	2148	<40	1884	580
MAY-2015	6898	739	2030	<40	1768	560
JUN-2015	6910	740	2257	<40	1891	580
JUL-2015	6937	738	2039	<40	1712	580

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1410	2265	100	6683	76	285
FEB-2014	1431	2152	73	496	67	490
MAR-2014	1433	2169	114	3726	98	340
APR-2014	1443	2144	112	128	90	400
MAY-2014	1414	2308	90	617	76	350
JUN-2014	1467	2052	96	423	82	380
JUL-2014	1459	2111	95	982	76	355
AUG-2014	1451	2161	87	208	72	365
SEP-2014	1451	2180	103	866	89	390
OCT-2014	1439	2250	84	257	62	395
NOV-2014	1452	2234	74	3945	64	400
DEC-2014	1472	2188	93	557	72	340
JAN-2015	1509	2069	105	1364	84	305
FEB-2015	1490	2140	98	74	84	380
MAR-2015	1462	2307	100	66	87	390
APR-2015	1469	2276	82	2279	66	475
MAY-2015	1451	2387	74	135	59	440
JUN-2015	1472	2305	93	115	85	430
JUL-2015	1469	2336	71	938	53	380

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1410	2	30	144	136	35	11493
FEB-2014	6548	1431	9	40	139	159	9	11537
MAR-2014	6573	1433	9	36	151	146	25	11581
APR-2014	6587	1443	5	27	159	161	14	11617
MAY-2014	6646	1414	14	38	191	152	59	11667
JUN-2014	6618	1467	7	24	142	183	-28	11705
JUL-2014	6659	1459	8	34	176	159	41	11749
AUG-2014	6683	1451	6	18	165	149	24	11781
SEP-2014	6713	1451	2	25	168	159	30	11820
OCT-2014	6738	1439	7	21	159	146	25	11847
NOV-2014	6732	1452	12	19	135	144	-6	11871
DEC-2014	6746	1472	7	39	136	148	14	11920
JAN-2015	6713	1509	13	24	148	185	-33	11955
FEB-2015	6766	1490	7	36	189	162	53	12007
MAR-2015	6820	1462	7	30	174	141	54	12048
APR-2015	6823	1469	14	29	169	174	3	12085
MAY-2015	6868	1451	9	33	169	146	45	12126
JUN-2015	6889	1472	4	36	152	163	21	12173
JUL-2015	6929	1469	0	26	164	148	40	12212

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	<b>6557</b>	0.72%	91.89%	6.31%	1.08%	<b>100.00%</b>
FEB-2014	50	6034	418	68	<b>6570</b>	0.76%	91.84%	6.36%	1.04%	<b>100.00%</b>
MAR-2014	50	6054	424	70	<b>6598</b>	0.76%	91.76%	6.43%	1.06%	<b>100.00%</b>
APR-2014	46	6067	422	76	<b>6611</b>	0.70%	91.77%	6.38%	1.15%	<b>100.00%</b>
MAY-2014	47	6138	418	74	<b>6677</b>	0.70%	91.93%	6.26%	1.11%	<b>100.00%</b>
JUN-2014	50	6107	416	71	<b>6644</b>	0.75%	91.92%	6.26%	1.07%	<b>100.00%</b>
JUL-2014	47	6147	415	73	<b>6682</b>	0.70%	91.99%	6.21%	1.09%	<b>100.00%</b>
AUG-2014	47	6170	414	72	<b>6703</b>	0.70%	92.05%	6.18%	1.07%	<b>100.00%</b>
SEP-2014	50	6185	424	71	<b>6730</b>	0.74%	91.90%	6.30%	1.05%	<b>100.00%</b>
OCT-2014	45	6208	434	73	<b>6760</b>	0.67%	91.83%	6.42%	1.08%	<b>100.00%</b>
NOV-2014	47	6217	424	70	<b>6758</b>	0.70%	91.99%	6.27%	1.04%	<b>100.00%</b>
DEC-2014	45	6231	421	74	<b>6771</b>	0.66%	92.02%	6.22%	1.09%	<b>100.00%</b>
JAN-2015	47	6185	440	74	<b>6746</b>	0.70%	91.68%	6.52%	1.10%	<b>100.00%</b>
FEB-2015	45	6228	451	73	<b>6797</b>	0.66%	91.63%	6.64%	1.07%	<b>100.00%</b>
MAR-2015	45	6297	436	67	<b>6845</b>	0.66%	91.99%	6.37%	0.98%	<b>100.00%</b>
APR-2015	44	6310	436	67	<b>6857</b>	0.64%	92.02%	6.36%	0.98%	<b>100.00%</b>
MAY-2015	46	6352	432	68	<b>6898</b>	0.67%	92.08%	6.26%	0.99%	<b>100.00%</b>
JUN-2015	48	6343	447	72	<b>6910</b>	0.69%	91.79%	6.47%	1.04%	<b>100.00%</b>
JUL-2015	45	6371	454	67	<b>6937</b>	0.65%	91.84%	6.54%	0.97%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3862 61%	36 86%	4269 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2431 38%	9 24%	2063 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3913 60%	24 77%	4287 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2546 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3905 60%	17 63%	4286 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3896 59%	19 79%	4269 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3875 59%	37 76%	4247 65%
JAN-2015	10 29%	2585 40%	10 29%	2222 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3850 59%	25 71%	4214 64%
FEB-2015	8 15%	2594 39%	8 15%	2229 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3887 59%	44 85%	4250 64%
MAR-2015	11 27%	2613 39%	11 27%	2256 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 73%	3921 59%	30 73%	4277 64%
APR-2015	11 31%	2630 40%	11 31%	2271 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 67%	3920 59%	24 67%	4276 64%
MAY-2015	8 20%	2644 40%	7 18%	2286 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3935 59%	33 83%	4289 64%
JUN-2015	10 21%	2637 39%	10 21%	2291 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3952 59%	37 79%	4303 64%
JUL-2015	6 15%	2663 40%	6 15%	2317 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	33 85%	3953 59%	33 85%	4303 64%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2133 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2107 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2075 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	933 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2032 60%	18 69%	958 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2047 60%	8 47%	968 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 32%	2029 60%	15 68%	985 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2006 59%	6 38%	1014 30%	0 0%	361 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1970 58%	10 56%	1030 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	2 13%	1963 58%	11 73%	1045 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1190 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	901 34%	2 25%	254 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	893 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	890 34%	1 13%	255 10%
APR-2015	4 67%	1149 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1141 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1136 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	7 88%	1123 44%	0 0%	311 12%	0 0%	880 34%	1 13%	260 10%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	76 5%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	74 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	74 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	336 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	350 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	358 19%	0 0%	74 4%	2 8%	881 48%	0 0%	1 0%
MAR-2015	10 53%	602 32%	5 26%	369 20%	0 0%	69 4%	4 21%	870 47%	0 0%	2 0%
APR-2015	7 50%	631 33%	4 29%	374 20%	2 14%	67 4%	1 7%	863 45%	0 0%	2 0%
MAY-2015	11 65%	667 34%	4 24%	383 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	713 35%	8 30%	397 20%	0 0%	72 4%	4 15%	876 43%	0 0%	1 0%
JUL-2015	12 60%	751 37%	4 20%	404 20%	0 0%	71 3%	4 20%	868 42%	0 0%	1 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2419	35.78	2190	32.40	1008	14.91	192	2.84	73	1.08	878	12.99
NOV-2014	2422	35.84	2159	31.95	1056	15.63	184	2.72	70	1.04	867	12.83
DEC-2014	2398	35.42	2145	31.68	1104	16.30	185	2.73	74	1.09	865	12.78
JAN-2015	2349	34.82	2125	31.50	1138	16.87	179	2.65	74	1.10	881	13.06
FEB-2015	2366	34.81	2112	31.07	1180	17.36	178	2.62	73	1.07	888	13.06
MAR-2015	2402	35.09	2113	30.87	1207	17.63	185	2.70	67	0.98	871	12.72
APR-2015	2395	34.93	2096	30.57	1243	18.13	184	2.68	67	0.98	872	12.72
MAY-2015	2404	34.85	2096	30.39	1279	18.54	178	2.58	68	0.99	873	12.66
JUN-2015	2370	34.30	2081	30.12	1327	19.20	170	2.46	72	1.04	890	12.88
JUL-2015	2378	34.28	2069	29.83	1356	19.55	170	2.45	67	0.97	897	12.93

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	30	2	5	5	8	8	393
APR-2015	29	8	3	4	3	11	340
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	26	6	2	3	6	7	365

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10026	2577
FEB-2014	10048	2570
MAR-2014	10061	2556
APR-2014	10091	2559
MAY-2014	10114	2552
JUN-2014	10149	2562
JUL-2014	10161	2550
AUG-2014	10210	2584
SEP-2014	10252	2594
OCT-2014	10274	2602
NOV-2014	10305	2624
DEC-2014	10346	2628
JAN-2015	10388	2658
FEB-2015	10434	2665
MAR-2015	10473	2673
APR-2015	10494	2684
MAY-2015	10548	2708
JUN-2015	10636	2756
JUL-2015	10716	2807

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
July 2015

N = 6937

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	13	15	10
	50+	18	28	12
	<b>Total HSDA:</b>	<b>31</b>	<b>43</b>	<b>22</b>
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	3	3	1
	35-49	18	24	13
	50+	45	60	35
	<b>Total HSDA:</b>	<b>67</b>	<b>88</b>	<b>50</b>
OKANAGAN	0-19	3	3	1
	20-34	20	21	17
	35-49	91	106	68
	50+	189	272	148
	<b>Total HSDA:</b>	<b>303</b>	<b>402</b>	<b>234</b>
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	16	16	11
	35-49	56	71	43
	50+	92	130	74
	<b>Total HSDA:</b>	<b>170</b>	<b>223</b>	<b>129</b>
<b>Total HA:</b>		<b>571</b>	<b>756</b>	<b>435</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	3
	20-34	39	40	29
	35-49	178	216	134
	50+	344	490	269
<b>Total HA:</b>		<b>571</b>	<b>756</b>	<b>435</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	443	599	341
Female	128	157	94

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	435	52	540	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	7	5
	<5 years	8	7
	<b>Total HSDA:</b>	<b>31</b>	<b>22</b>
KOOTENAY BOUNDARY	10 years or more	31	21
	5 years or more	18	14
	<5 years	18	15
	<b>Total HSDA:</b>	<b>67</b>	<b>50</b>
OKANAGAN	10 years or more	162	118
	5 years or more	72	56
	<5 years	69	60
	<b>Total HSDA:</b>	<b>303</b>	<b>234</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	85	57
	5 years or more	35	32
	<5 years	50	40
	<b>Total HSDA:</b>	<b>170</b>	<b>129</b>
<b>Total HA:</b>		<b>571</b>	<b>435</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	294	206
	5 years or more	132	107
	<5 years	145	122
<b>Total HA:</b>		<b>571</b>	<b>435</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	34	46	12	19
KOOTENAY BOUNDARY	59	106	26	40
OKANAGAN	189	639	72	226
THOMPSON/CARIBOO/SHUSWAP	122	405	43	104
<b>Total:</b>	<b>404</b>	<b>1196</b>	<b>153</b>	<b>389</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	12
OKANAGAN	40
THOMPSON/CARIBOO/SHUSWAP	39
<b>Total:</b>	<b>92</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	23	24	17
	35-49	121	133	99
	50+	159	217	128
	<b>Total HSDA:</b>	<b>310</b>	<b>381</b>	<b>249</b>
FRASER NORTH	0-19	19	19	3
	20-34	111	112	98
	35-49	357	409	262
	50+	442	686	362
	<b>Total HSDA:</b>	<b>929</b>	<b>1226</b>	<b>725</b>
FRASER SOUTH	0-19	13	13	6
	20-34	92	94	75
	35-49	357	405	295
	50+	401	593	339
	Unknown	0	1	0
	<b>Total HSDA:</b>	<b>863</b>	<b>1106</b>	<b>715</b>
<b>Total HA:</b>		<b>2102</b>	<b>2713</b>	<b>1689</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	39	39	14
	20-34	226	230	190
	35-49	835	947	656
	50+	1002	1496	829
	Unknown	0	1	0
<b>Total HA:</b>		<b>2102</b>	<b>2713</b>	<b>1689</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1586	2080	1294
Female	516	633	395

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1689	49	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	140	109
	5 years or more	89	72
	<5 years	81	68
	<b>Total HSDA:</b>	<b>310</b>	<b>249</b>
FRASER NORTH	10 years or more	438	319
	5 years or more	234	187
	<5 years	257	219
	<b>Total HSDA:</b>	<b>929</b>	<b>725</b>
FRASER SOUTH	10 years or more	390	311
	5 years or more	231	193
	<5 years	242	211
	<b>Total HSDA:</b>	<b>863</b>	<b>715</b>
<b>Total HA:</b>		<b>2102</b>	<b>1689</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	968	739
	5 years or more	554	452
	<5 years	580	498
<b>Total HA:</b>		<b>2102</b>	<b>1689</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	125	389	42	70
FRASER NORTH	223	1346	62	269
FRASER SOUTH	200	1150	49	353
<b>Total:</b>	<b>548</b>	<b>2885</b>	<b>153</b>	<b>692</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	183
FRASER NORTH	610
FRASER SOUTH	483
<b>Total:</b>	<b>1276</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	20	20	16
	35-49	86	100	67
	50+	193	312	167
	<b>Total HSDA:</b>	<b>301</b>	<b>434</b>	<b>250</b>
RICHMOND	0-19	7	7	1
	20-34	21	21	20
	35-49	46	49	37
	50+	72	111	57
	<b>Total HSDA:</b>	<b>146</b>	<b>188</b>	<b>115</b>
VANCOUVER	0-19	58	61	8
	20-34	412	421	324
	35-49	1639	1917	1227
	50+	2324	3852	1853
	<b>Total HSDA:</b>	<b>4433</b>	<b>6251</b>	<b>3412</b>
<b>Total HA:</b>		<b>4880</b>	<b>6873</b>	<b>3777</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	67	70	9
	20-34	453	462	360
	35-49	1771	2066	1331
	50+	2589	4275	2077
<b>Total HA:</b>		<b>4880</b>	<b>6873</b>	<b>3777</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4287	6040	3338
Female	591	831	439

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3777	51	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	165	129
	5 years or more	49	45
	<5 years	87	76
	<b>Total HSDA:</b>	<b>301</b>	<b>250</b>
RICHMOND	10 years or more	69	50
	5 years or more	34	25
	<5 years	43	40
	<b>Total HSDA:</b>	<b>146</b>	<b>115</b>
VANCOUVER	10 years or more	2187	1574
	5 years or more	1094	868
	<5 years	1152	970
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4433</b>	<b>3412</b>
<b>Total HA:</b>	<b>4880</b>	<b>3777</b>	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2421	1753
	5 years or more	1177	938
	<5 years	1282	1086
	Never on ART	0	0
<b>Total HA:</b>		<b>4880</b>	<b>3777</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	136	358	54	88
RICHMOND	42	269	14	92
VANCOUVER	521	9628	206	5207
<b>Total:</b>	<b>699</b>	<b>10255</b>	<b>274</b>	<b>5387</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	2
VANCOUVER	103
<b>Total:</b>	<b>111</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	22	24	17
	35-49	85	99	75
	50+	151	243	120
	<b>Total HSDA:</b>		<b>260</b>	<b>368</b>
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	13	14	8
	35-49	36	40	31
	50+	56	84	47
	<b>Total HSDA:</b>		<b>107</b>	<b>140</b>
SOUTH VANCOUVER ISLAND	0-19	8	8	1
	20-34	40	42	31
	35-49	211	251	165
	50+	371	579	296
	<b>Total HSDA:</b>		<b>630</b>	<b>880</b>
<b>Total HA:</b>		<b>997</b>	<b>1388</b>	<b>793</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	3
	20-34	75	80	56
	35-49	332	390	271
	50+	578	906	463
<b>Total HA:</b>		<b>997</b>	<b>1388</b>	<b>793</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	805	1124	643
Female	192	264	150

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	793	52	460	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	121	95
	5 years or more	64	54
	<5 years	75	64
	<b>Total HSDA:</b>	<b>260</b>	<b>213</b>
NORTH VANCOUVER ISLAND	10 years or more	47	38
	5 years or more	24	20
	<5 years	36	29
	<b>Total HSDA:</b>	<b>107</b>	<b>87</b>
SOUTH VANCOUVER ISLAND	10 years or more	306	213
	5 years or more	157	130
	<5 years	167	150
	<b>Total HSDA:</b>	<b>630</b>	<b>493</b>
<b>Total HA:</b>		<b>997</b>	<b>793</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	474	346
	5 years or more	245	204
	<5 years	278	243
<b>Total HA:</b>		<b>997</b>	<b>793</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	529	81	173
NORTH VANCOUVER ISLAND	112	229	46	70
SOUTH VANCOUVER ISLAND	180	1494	47	516
<b>Total:</b>	<b>458</b>	<b>2252</b>	<b>174</b>	<b>759</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	45
NORTH VANCOUVER ISLAND	30
SOUTH VANCOUVER ISLAND	76
<b>Total:</b>	<b>151</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	6	7	4
	35-49	18	20	11
	50+	16	21	10
	<b>Total HSDA:</b>	<b>41</b>	<b>49</b>	<b>25</b>
NORTH WEST	0-19	1	1	0
	20-34	8	12	7
	35-49	27	39	24
	50+	30	45	23
	<b>Total HSDA:</b>	<b>66</b>	<b>97</b>	<b>54</b>
NORTHERN INTERIOR	0-19	2	2	1
	20-34	29	32	21
	35-49	73	89	59
	50+	71	116	55
	<b>Total HSDA:</b>	<b>175</b>	<b>239</b>	<b>136</b>
<b>Total HA:</b>		<b>282</b>	<b>385</b>	<b>215</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	4	4	1
	20-34	43	51	32
	35-49	118	148	94
	50+	117	182	88
<b>Total HA:</b>		<b>282</b>	<b>385</b>	<b>215</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	179	247	137
Female	103	138	78

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	215	47	500	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	7
	5 years or more	10	8
	<5 years	16	10
	<b>Total HSDA:</b>	<b>41</b>	<b>25</b>
NORTH WEST	10 years or more	17	9
	5 years or more	21	19
	<5 years	28	26
	<b>Total HSDA:</b>	<b>66</b>	<b>54</b>
NORTHERN INTERIOR	10 years or more	49	30
	5 years or more	48	41
	<5 years	78	65
	<b>Total HSDA:</b>	<b>175</b>	<b>136</b>
<b>Total HA:</b>		<b>282</b>	<b>215</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	81	46
	5 years or more	79	68
	<5 years	122	101
<b>Total HA:</b>		<b>282</b>	<b>215</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	30	56	7	10
NORTH WEST	60	139	19	25
NORTHERN INTERIOR	95	375	23	180
<b>Total:</b>	<b>185</b>	<b>570</b>	<b>49</b>	<b>215</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	19
<b>Total:</b>	<b>45</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	7
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	8
	THOMPSON/CARIBOO/SHUSWAP	22	37	18
	<b>Total HA:</b>	<b>47</b>	<b>81</b>	<b>36</b>
FRASER	FRASER EAST	32	40	27
	FRASER NORTH	59	88	43
	FRASER SOUTH	67	93	55
	<b>Total HA:</b>	<b>158</b>	<b>221</b>	<b>125</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	42	19
	RICHMOND	9	14	7
	VANCOUVER	492	765	405
	<b>Total HA:</b>	<b>524</b>	<b>821</b>	<b>431</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	46	71	34
	NORTH VANCOUVER ISLAND	13	22	11
	SOUTH VANCOUVER ISLAND	33	70	26
	<b>Total HA:</b>	<b>92</b>	<b>163</b>	<b>71</b>
NORTHERN	NORTH EAST	10	12	5
	NORTH WEST	32	55	29
	NORTHERN INTERIOR	62	92	55
	<b>Total HA:</b>	<b>104</b>	<b>159</b>	<b>89</b>
<b>Total:</b>		<b>925</b>	<b>1445</b>	<b>752</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	589	933	471
Female	336	512	281

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	752	49	460	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Combination Therapy:** using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Complera (CPL):** the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

**Efavirenz (Sustiva, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

**Emtricitabine (FTC):** a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**Famciclovir (Famvir):** a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.





**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (MVC, Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).







**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

**Tenofovir (Viread, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Trizivir (TRZ):** ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Truvada (TRU):** the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

